美因基因(06667.HK)2022年度業績:經調整淨利潤284.4萬元、同比下降97.3%
格隆匯3月31日丨美因基因(06667.HK)披露2022年度業績,實現收入1.46億元(人民幣,下同),同比下降38.6%;毛利8172.3萬元,同比下降51.0%;毛利率56.1%,同比下降14.2個百分點;經調整淨利潤284.4萬元,同比下降97.3%。
消費級基因檢測服務和癌症篩查服務同比收入下降,乃由於2022年全國多地區、持續性、長時間爆發新型冠狀病毒疫情,多個大中城市持續封控限流,客户到檢受限所致。
截至2022年12月31日止年度,癌症篩查服務的毛利率為71.9%,同比下降3.8個百分點,主要原因是2022年推廣並普及癌症篩查服務,公司調整價格策略。消費級基因檢測服務毛利率為43.3%,同比降低22.9個百分點,乃由於收入大幅減少,人工、房租等固定支出相對固定,毛利減少,毛利率降低。
經調整淨利潤大幅下降主要乃由於公司收入降低導致毛利大幅減少,此外公司加大市場推廣力度,增加營銷人員儲備導致人員成本增加;同時,隨着研發進度推進,部分項目進入到臨牀實驗階段,研發人員增加,人工、試劑、測序等各種費用增加;另外,由於新型冠狀病毒疫情的影響,多個大中城市持續封控限流,體檢中心門店閉店,公司回款受到較大影響,信用減值損失計提金額大幅增加。
自2016年成立以來,公司的研發一直是擴展公司檢測技術平台及檢測服務產品的中堅力量。公司採取以市場為導向的研發戰略。公司的研發團隊通過跟蹤行業發展、市場需求及競爭,以及識別具有巨大商業化市場潛力的服務及產品,助力公司發展戰略的制定。截至2022年12月31日止年度,公司的研發開支與2021年同期相比增加70%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.